Cargando…

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrivastava, Trilok, Van Rhee, Frits, Al Hadidi, Samer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290473/ https://www.ncbi.nlm.nih.gov/pubmed/37359353 http://dx.doi.org/10.2147/OTT.S370880

Ejemplares similares

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages
por: Nobari, Shirin Teymouri, et al.
Publicado: (2022)

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
por: Al Hadidi, Samer, et al.
Publicado: (2017)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
por: Hussain, Munawwar, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
por: Bu, De-Xiu, et al.
Publicado: (2018)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
por: Abramson, Hanley N.
Publicado: (2020)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review
por: Anampa-Guzmán, Andrea, et al.
Publicado: (2022)

The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma
por: Xu, Yanjie, et al.
Publicado: (2023)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
por: Perez-Amill, Lorena, et al.
Publicado: (2020)

Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
por: Tang, Fang, et al.
Publicado: (2020)

Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells
por: Dai, Ying, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
por: Huo, Jianxin, et al.
Publicado: (2022)

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
por: Ghermezi, Michael, et al.
Publicado: (2017)

Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
por: Ali, Mohammad O., et al.
Publicado: (2023)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4otu96d845dgham3he30df29ib